Scholar Rock

Q2 FY2026 EarningsQ2 FY26 results were largely in-line with consensus on EPS, though the net loss was slightly higher than anticipated. The company reported a GAAP EPS of -$0.84 vs. the -$0.85 consensus, while Net Loss (GAAP) of $109.9M was $1.9M wider than the $108.0M expected. Operating expenses decreased 2.9% YoY to $108.9M, primarily driven by lower drug manufacturing costs for apitegromab as Phase 3 trials concluded. Total cash and marketable securities rose to $492.1M following $200M in new debt drawdowns and $160.8M in ATM sales, extending the cash runway into H2 2027.